الفهرس 
Title : The relation between angiotensin converting enzyme inhibitors and hepatoma in Egyptian patients
AbstractOnly 14 pages are availabe for public view
 |  | from | 264 |  |  |
| | | from | 264 | | |
Abstract
This study was conducted to investigate the association between angiotensin converting enzyme inhibitors (ACE-I) and hepatocellular carcinoma (HCC) in Egyptians forty patients with HCC, (23 patients with Child-Pugh B and 17 patients with Child-Pugh C) compared with eight normal control humans, which diagnosed by physicians of the Damietta Cancer Institute according to (AASLD) Practice Guidelines. Patients received Captopril at 50 mg/day for 3 months; the samples were collected before and directly after the end of given of Captopril. Serum Alfa fetoprotein (AFP), Vascular Endothelial Growth Factor (VEGF) and liver functions were evaluated before and after of administration of Captopril. P- Value, R- ratio and prognostic value, Receiver Operating characteristic (ROC) curves were used for association studies and to assess the differences in the values among the groups. There was statistically significant improvement of serum liver functions, and decreased serum AFP and VEGF levels in HCC patients at post-administration compared with pre-administration of Captopril. In addition, at pre-administration there was significant correlation of serum VEGF with serum AFP (r = 0.492) and at post- administration with serum AFP (r = 0.619). The prognostic value of serum AFP and VEGF levels were assessed by ROC curve showing an area under curve (AUC) of (0.689, 0.907), respectively for identifying patients with HCC pre- and post-administration of Captopril. In conclusion, ACE inhibitors (as Captopril), were significantly inhibit tumor growth and angiogenesis along with suppression of the serum VEGF and AFP levels. This may be used in the clinical trials as anti-angiogenic agents against cancer, and may be applicable as an anticancer agent providing a new strategy for cancer therapy